drugset / Trial / NCT00796458

Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer

NCT00796458 ↗

Phase 3 Unknown 200 enrolled A.O.U. San Giovanni Battista di Torino, Italy
RandomizedOpen-labelTreatment

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving androgen ablation therapy together with docetaxel is more effective than giving androgen ablation therapy alone in treating patients with advanced prostate cancer. PURPOSE: This randomized phase III trial is studying androgen ablation and docetaxel to see how well they work compared with androgen ablation alone in treating patients with advanced prostate cancer.

Timeline

Start
2005-04
Primary completion
2013-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — Intravenous

Indications